STOCK TITAN

Integrated BioPharma (INBP) director awarded 50,000 stock options at $0.19 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

INTEGRATED BIOPHARMA INC director Eric J. Friedman received a grant of stock options for 50,000 shares of Common Stock. These options have an exercise price of $0.1900 per share and expire on June 24, 2036. The grant is compensation-related rather than an open‑market purchase.

The options vest and become exercisable in four equal installments of 12,500 options each on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, aligning vesting with future service periods.

Positive

  • None.

Negative

  • None.
Insider Friedman Eric J
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 50,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 50 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 50,000 options Stock Option (Right to Buy) granted to director
Exercise price $0.1900 per share Strike price for underlying Common Stock
Expiration date June 24, 2036 Option term end date
First vesting tranche 12,500 options Vesting on September 30, 2026
Second vesting tranche 12,500 options Vesting on December 31, 2026
Third vesting tranche 12,500 options Vesting on March 31, 2027
Fourth vesting tranche 12,500 options Vesting on June 30, 2027
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "0.1900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The stock options vest and become exercisable in four equal installments"
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Friedman Eric J

(Last)(First)(Middle)
C/O INTEGRATED BIOPHARMA, INC.
225 LONG AVENUE, BLDG 15

(Street)
HILLSIDE NEW JERSEY 07205

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.1906/24/2026A50,000 (1)06/24/2036Common Stock50,000$050D
Explanation of Responses:
1. The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.
/s/ Eric Friedman06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Eric J. Friedman do in this INBP Form 4 filing?

Director Eric J. Friedman received a grant of 50,000 stock options for Integrated BioPharma Inc. These options are a compensation award, not an open-market share purchase or sale, and give him the right to buy common stock at a fixed exercise price.

What are the key terms of Eric J. Friedman’s new INBP stock options?

The grant covers 50,000 stock options on Integrated BioPharma common stock with a $0.1900 exercise price per share. The options expire on June 24, 2036, providing a long-term opportunity to acquire shares if the stock trades above the exercise price.

How do the INBP stock options granted to Eric J. Friedman vest?

The 50,000 stock options vest in four equal installments of 12,500 each. Vesting dates are September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, meaning Friedman gains exercisability gradually over this period.

Is Eric J. Friedman’s Form 4 transaction a buy or sell of INBP shares?

The Form 4 reports an acquisition of derivative securities through a grant, not a market buy or sell. The transaction code is “A,” indicating a grant or award of stock options rather than an open-market purchase or disposition of Integrated BioPharma common shares.

What does the expiration date mean for Eric J. Friedman’s INBP options?

The options expire on June 24, 2036, after which any unexercised options become worthless. Until then, once vested, Friedman may choose to exercise them at $0.1900 per share if market conditions make exercising economically attractive compared with the current stock price.